

## Comparative Study Between Oral and Intralesional Injection of Beta Blocker in the Treatment of Infantile Capillary Hemangioma

**Authors :** Nadeen Eltokhy, Sahar S. Sheta, Walaa Elnaggar, Karim Bakr

**Abstract :** Purpose: The aim of this study is to compare the clinical efficacy and side effects of oral versus intralesional propranolol treatment of infantile capillary hemangiomas in infants. Methods: The study enrolled 40 infants diagnosed with infantile capillary hemangiomas. Patients were divided into 2 groups: Group A (Non-invasive group) included 20 infants who received oral propranolol hydrochloride starting at a dose of 1 mg/kg/day BID, then increased to a max of 2 mg/kg/day BID gradually over 2 weeks for 3 months. Group B (Invasive group) included 20 infants who received intralesional propranolol injection at a dose of 1 mg/mL; the volume of the injected drug depended on the size of the lesion (0.2 mL injected per cm of lesion diameter), with a maximum volume of 1 mL for a lesion of 5 cm diameter under complete aseptic conditions in the operating theater. Results: At three months after initiating treatment, the circumferential size of the hemangioma showed a statistically significant decrease in both groups; in Group A from  $3.66 \pm 2.89$  cm to  $1.56 \pm 1.26$  cm with p-value  $< 0.05$  and in Group B from  $2.99 \pm 2.73$  cm to  $1.32 \pm 1.18$  cm with p-value  $< 0.05$ . There is no statistically significant comparative difference between the two groups (p-value = 0.538 = insignificant). Regarding the complications of oral propranolol, one patient (5%) had bradycardia, and one patient (5%) had diarrhea. In the injection group, 20 patients (100%) had local edema, and one patient (5%) had a local infection. Conclusions: Both oral non-invasive and intralesional invasive propranolol are safely used to successfully treat and decrease the size of infantile hemangioma while showing no statistically comparative difference between both treatment techniques.

**Keywords :** hemangioma, oral beta blocker, intralesional beta blocker, infants

**Conference Title :** ICPCH 2024 : International Conference on Paediatrics and Child Health

**Conference Location :** New York, United States

**Conference Dates :** May 23-24, 2024